Roche

News

England to start screening newborns for rare disease SMA

All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.

News

Roche abandons two Huntington's drug candidates

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Roche looks to Astex in $515m breast cancer deal

Roche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

Bispecific antibody firm Ollin raises $330m in bumper round

Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.

News

FDA approves first generic of Roche's flu drug Xofluza

The first generic of Roche's drug for influenza, Xofluza, has been approved by the FDA and should be available in time for this year's flu season.

England to start screening newborns for rare disease SMA

Roche abandons two Huntington's drug candidates

Roche looks to Astex in $515m breast cancer deal

Roche's KRAS drug tops its rivals in lung cancer trial

Bispecific antibody firm Ollin raises $330m in bumper round

FDA approves first generic of Roche's flu drug Xofluza

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks